Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Bionano Genomics Has a Story That Investors Should Get Behind

By Chris Markoch, InvestorPlace Contributor

BNGO stock is up 280% this year as its story begins to unfold. The stock may cool off, but it looks like there are many chapters to come for the firm.

Gevo Is a Speculative Bet Without More Revenue

By Chris Markoch, InvestorPlace Contributor

Gevo stock may be worth a speculative bet as part of your clean energy portfolio, but probably not at its current price.

The Easy Gains of Foresight Autonomous Stock Are Long Gone

By Chris Markoch, InvestorPlace Contributor

FRSX stock is up 181% for the year. But with the bulls and the bears fighting over the stock, the hard work of justifying its valuation is now at hand.

7 Reddit Stocks That Deserve to Go Bankrupt

By Chris Markoch, InvestorPlace Contributor

Reddit stocks continue to captivate. Although many retail investors have made shrewd profits, some low-priced stocks carry a bankruptcy risk.

Don’t Buy Ideanomics Stock Before the Company Figures Out What It’s Doing

By Chris Markoch, InvestorPlace Contributor

Ideanomics appears to have two potentially viable businesses. But it remains to be seen if it has a core competency in either one, and that's the risk of IDEX stock.

Load More